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ABSTRACT
It is known that transcription can induce DNA
recombination, thus compromising genomic stabil-
ity. RECQ5 DNA helicase promotes genomic sta-
bility by regulating homologous recombination.
Recent studies have shown that RECQ5 forms a
stable complex with RNA polymerase II (RNAPII) in
human cells, but the cellular role of this association
is not understood. Here, we provide evidence
that RECQ5 specifically binds to the Ser2,5-
phosphorylated C-terminal repeat domain (CTD) of
the largest subunit of RNAPII, RPB1, by means of a
Set2–Rpb1-interacting (SRI) motif located at the
C-terminus of RECQ5. We also show that RECQ5
associates with RNAPII-transcribed genes in a
manner dependent on the SRI motif. Notably,
RECQ5 density on transcribed genes correlates
with the density of Ser2-CTD phosphorylation,
which is associated with the productive elongation
phase of transcription. Furthermore, we show that
RECQ5 negatively affects cell viability upon
inhibition of spliceosome assembly, which can
lead to the formation of mutagenic R-loop
structures. These data indicate that RECQ5 binds
to the elongating RNAPII complex and support the
idea that RECQ5 plays a role in the maintenance of
genomic stability during transcription.
INTRODUCTION
The numerous processes that occur in the nucleus during
cell proliferation have to be tightly coordinated to ensure
genome integrity and faithful genome propagation.
Transcription is known to stimulate DNA recombination,
thus affecting genome stability (1). This phenomenon,
called transcription-associated recombination (TAR),
has been linked to replication fork pausing that results
from the convergence of transcription and replication.
TAR has also been linked to the formation RNA:DNA
hybrids (R-loops) between the nascent transcript and the
template DNA strand, which increases the susceptibility
of the non-transcribed strand to damage or to the
formation of secondary structures that impair replication
fork progression (1). R-loops are formed when the
co-transcriptional assembly of mRNA-particle complexes
is impaired (1). For example, it has been shown that in-
activation of the human SR protein ASF/SF2, which is
required for spliceosome assembly, results in DNA frag-
mentation, cell-cycle arrest and genomic instability as a
consequence of R-loop formation (2). ASF/SF2 depletion
also leads to accumulation of stalled replication forks, and
chromosome breaks caused by ASF/SF2 deﬁciency occur
speciﬁcally in S-phase, preferentially at gene-rich regions
(3). These data suggest that TAR results as a consequence
of replication fork collapse at R-loops (3).
RECQ5 belongs to the RecQ family of DNA helicases
that play critical roles in the maintenance of genomic sta-
bility and cancer suppression (4). Recent studies in mam-
malian cells have established RECQ5 as an important
anti-recombination factor that acts by controlling the
assembly of the RAD51 ﬁlament on single-stranded
DNA (ssDNA), which catalyses the homology search
and strand invasion during homologous recombination
(HR) (5,6). RECQ5 binds directly to the RAD51 recom-
binase and disrupts the RAD51-ssDNA ﬁlament in
a reaction driven by ATP hydrolysis, thus preventing
homologous duplex invasion during HR (6). In accord-
ance with this ﬁnding, RECQ5-deﬁcient cells versus
RECQ5-proﬁcient cells show an increased efﬁciency of
HR-mediated DNA double-strand break (DSB) repair,
an elevated frequency of sister chromatid exchange, a
prolonged persistence of RAD51 foci in response to
DNA damage and an increased rate of chromosomal
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to accumulate at sites of DSBs and sites of replication
arrest in a manner dependent on the MRE11–RAD50–
NBS1 complex, a key player in DNA damage signaling
and repair (7).
A number of recent proteomic studies have revealed
that RECQ5 forms a stable complex with RNA polymer-
ase II (RNAPII) in human cells (7–9). The RECQ5–
RNAPII interaction is direct and is mediated by the
largest subunit of RNAPII, RPB1 (8). Knockdown of
the RECQ5 transcript in human cells has been found to
increase the transcription of several genes (9). Likewise,
RECQ5 has been shown to inhibit RNAPII transcription
in an in vitro system reconstituted using puriﬁed proteins
(10). Despite these ﬁndings, the function of RECQ5
during the RNAPII transcription cycle remains elusive.
Here, we provide evidence that RECQ5 associates with
RNAPII during the productive elongation phase of tran-
scription through direct binding to the C-terminal repeat
domain (CTD) of RPB1. Moreover, we show that deple-
tion of RECQ5 reduces the cellular sensitivity to
diospyrin, a plant-derived bisnaphthoquinonoid, which
interferes with spliceosome assembly, presumably by in-
hibiting DNA topoisomerase I (Top1)-mediated phos-
phorylation of ASF/SF2, and hence is likely to promote
formation of R-loops during RNAPII transcription (3,11).
These ﬁndings are discussed in light of a possible role for
RECQ5 in promoting genomic stability at sites of
RNAPII transcription.
MATERIALS AND METHODS
Plasmids, proteins and antibodies
The vector pTXB1 (New England Biolabs) was used for
bacterial expression of wild-type and mutant forms of
human RECQ5 as fusions with the self-cleaving chitin-
binding domain (CBD) tag. Construction of these
plasmids was previously described (12). The expression
vector for RECQ5 908–954 (SRI) was constructed
in the same way as the vector for RECQ5 640–653
(12). Point mutations in RECQ5 were made using
QuickChange Site-Directed Mutagenesis Kit
(Stratagene). The vector pLexA-Km (Dualsystems) was
used for construction of the yeast two-hybrid bait
plasmids carrying different parts of the human RECQ5
cDNA. RECQ5 cDNA was ampliﬁed by PCR and
ligated in pLexA-Km via EcoRI and SalI sites in frame
with a LexA DNA-binding domain. Internal deletions and
point mutations of RECQ5 were subcloned from the
pTXB1 constructs. To express RECQ5 and its mutants
in human cells as N-terminal fusions with green ﬂuores-
cent protein (GFP), the respective RECQ5 cDNA cloned
in the pTXB1 vector was PCR ampliﬁed using Phusion
high-ﬁdelity DNA polymerase (Finnzymes) and the fol-
lowing set of primers: 50-AAACTCGAGCTATGAGCA
GCCACCATACC-30 and 50 AAAGAATTCTCTCTGG
GGGCCACACAGGCCTAA-30. The resulting amplicon
was digested and cloned into pEGFP-C1 (Clontech)
between the XhoI and EcoRI sites. The RECQ5 protein
and its mutants were produced in bacteria as fusions with
CBD and puriﬁed as described previously (13). The
antibodies used in this study are listed in Supplementary
Table S1.
Cell culture
HeLa, HEK293 and HEK293T cells were maintained in
DMEM (Gibco) containing 5% fetal calf serum (Gibco)
and 100 U/ml penicillin/streptomycin. Transfections of
HEK293 cells were carried out using the TransIT-LT1
reagent according to the manufacturer’s instructions
(Invitrogen). Transfection efﬁciency was >90% as deter-
mined by visualization of GFP expression using a ﬂuores-
cence microscope 48h post-transfection. Transfection of
siRNA oligonucleotides (Microsynth) was carried out
using Lipofectamine RNAiMAX (Invitrogen) according
to manufacturer’s instructions. The following oligo-
nucleotides were used: siRECQ5#1 (sense strand): 50-CA
GGAGGCUGAUAAAGGGUUA-30; siRECQ5#2 (sense
strand): 50-GGAGAGUGCGACCAUGGCU-30; and
siCtrl (sense strand): 50-CGUACGCGGAAUACUUC
GA-30.
Yeast two-hybrid assay
The yeast two-hybrid screen for proteins that interact with
RECQ5 was carried out using Saccharomyces cerevisiae
strain L40 (MATa trp1 leu2 his3 LYS2::lexA-HIS3
URA3::lexA-lacZ), which was sequentially transformed
with the bait plasmid encoding the LexA-RECQ5
411-991 and a randomly primed human peripheral blood
cDNA library cloned into the BglII sites of pACT
(Clontech). Among the 1.4 10
7 transformants tested
for histidine prototrophy and b-galactosidase staining,
198 positive clones were found. Clones carrying the
bait and prey plasmids were tested for b-galactosidase
activity using a pellet X-gal (PXG) assay as previously
described (14).
Far western assay
Far western assays were performed as described previ-
ously (15). Brieﬂy, duplicate samples of  1.5mg of the
puriﬁed proteins were separated on a 4–20% Criterion
gel (Bio-Rad). One half of the gel was stained with
Coomassie brilliant blue and the second half was
transferred to nitrocellulose membrane. The membrane
was incubated overnight at 4 C in blocking/renaturation
buffer, containing 1  PBS, 3% non-fat dry milk, 0.2%
Tween 20, 0.1% PMSF, 5mM NaF and 2mM
dithiothreitol. The nitrocellulose was then probed with
 300000 cpm [
32P]-labeled GSTyCTD fusion protein
that had been hyperphosphorylated with CTDK-I for
4h at 4 C. After extensive washing, the nitrocellulose
was air-dried and subjected to autoradiography.
Immobilized CTD peptide binding assay
Synthetic biotinylated peptides were dissolved in PBS and
incubated with 300ml of TetraLink Tetrameric Avidin
Resin (Invitrogen) for 45min at room temperature (RT).
The peptide concentrations in the column onput,
ﬂow-through and wash fractions were monitored by
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approximate the amount of peptide on the column.
Generally, 30–50mg of biotinylated peptide was
conjugated to the 300ml column. The peptide columns
were stored in PBS at 4 C and were stable for  2
months. Approximately 10–15mg of puriﬁed protein and
50mg insulin were dissolved in PBS for a ﬁnal volume of
500ml as the onput; 450ml of the onput was applied to the
peptide resin and incubated for 20min at RT with mixing
every for 5min. The ﬂow-through and two washes with
half-column volumes of PBS were collected. The resin was
then extensively washed with 5ml of buffer containing
25mM HEPES (pH 7.6), 8% glycerol, 150mM NaCl
and 0.1mM EDTA (HGNE150). The bound protein was
then eluted with four half-column volumes of HGNE300
and four half-column volumes of HGNE1000. The resin
was regenerated with 5ml HGNE1000 and 5ml PBS.
Samples were analyzed by SDS–PAGE followed by
Coomassie blue staining.
CBD pull-down assay
CBD-tagged RECQ5 and its variants were produced
in Escherichia coli BL21-CodonPlus(DE3)-RIL cells
(Stratagene) and immobilized on chitin beads (20ml;
New England Biolabs) as previously described (7). Beads
were incubated for 2h at 4 C with a total extract from
HEK293T cells (600mg of protein) in a volume of 500ml
of buffer TN2 [50mM Tris–HCl (pH 8), 120mM NaCl,
20mM NaF, 15mM sodium pyrophosphate and 0.5%
(v/v) NP-40] supplemented with 1mM benzamidine,
0.2mM PMSF, 0.5mM sodium orthovanadate and
protease inhibitor cocktail (Roche) and then were
washed three times with buffer TN2. Bound proteins
were released from the beads by addition of 25mlo f3  
SDS-loading buffer followed by incubation at 95 C
for 7min. Eluted proteins were separated by 10% SDS–
PAGE and analyzed by western blotting using the
indicated antibodies. RECQ5 was detected by Ponceau S
staining.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were
performed using the ChIP-IT Express kit from Active
Motif (Carlsbad, CA, USA) according to manufacturer’s
instructions. Brieﬂy, HeLa or 293 (mock or GFP-RECQ5
transfected) cells grown to 70-80% conﬂuency were
crosslinked with 1% formaldehyde (Sigma) at RT for
10min, and glycine (0.125M) was added to stop the
reaction. Isolated nuclei were then sheared using a
Bioruptor sonicator (Diagenode, Liege, Belgium) to
obtain chromatin fragments between 200 and 500bp.
Ten percent of the sonicated chromatin was reserved for
use as an input DNA control. For each ChIP reaction,
 6.3mg of crosslinked chromatin were immun-
oprecipitated overnight at 4 C with 4mg of a speciﬁc
antibody or control IgG. After elution of immune
complexes and reversion of crosslinking, DNA was re-
covered by using the QIAquick PCR Puriﬁcation Kit
(Qiagen).
Quantitative real-time PCR
The amount of immunoprecipitated DNA in each ChIP
reaction was measured by quantitative real-time PCR
(qPCR) using a Roche LightCycler 480 Real-Time PCR
System and a Roche LightCycler 480 DNA SYBR Green I
Master. Primer sequences used for the qPCR reactions are
listed in Supplementary Table S2. Speciﬁcity of target
ampliﬁcation was conﬁrmed by agarose gel electrophor-
esis and melting curve analysis. For each primer pair, a
series of 5-fold dilutions of input DNA were used to
generate a linear standard curve in which the crossing
point was plotted versus log10 of template concentration.
Primer pair efﬁciency was calculated from these data as
E=10
( 1/slope), and primer pairs with E>1.8 were used
for qPCR. For data analysis, Pfafﬂ’s method was used
(16). Fold enrichment of immunoprecipitated target
regions was expressed as ratio of the amount of DNA
estimated for a speciﬁc antibody versus the amount of
DNA estimated for the control IgG antibody. All qPCR
reactions were performed at least six times using DNA
template obtained from two independent ChIP experi-
ments. The data were plotted using GraphPad Prism
software as mean±SEM.
Helicase assay
PAGE-puriﬁed DNA and RNA oligonucleotides used for
helicase assays were purchased from Microsynth. The se-
quences are: deoxy-18 (d18): 50-tcc cag tca cga cgt tgt-30;
ribo-18 (r18): 50-ucc cag uca cga cgu ugu-30. The oligo-
nucleotides were 50-end labeled with T4 polynucleotide
kinase and g[
32P]ATP (GE HealthCare) and annealed to
M13mp2 ssDNA at a 1 : 1 (mol/mol) ratio in the presence
of 20mM Tris–HCl (pH 7.4) and 150mM NaCl. For
helicase assays, RECQ5 at concentrations ranging from
0 to 360nM was incubated either with 1nM M13mp2/
d18 or with 1nM M13mp2/r18 substrate for 30min at
37 Ci n1 0ml of 33mM Tris–acetate buffer (pH 7.9) con-
taining 10mM Mg-acetate, 66mM K-acetate, 0.1mg/ml
BSA and 2mM ATP. Helicase reactions were stopped
by addition of 2.5mlo f5   stop dye (100mM EDTA,
60% glycerol, 1.5% SDS, 0.1% bromophenol blue and
0.1% xylene cyanol). Products were separated by electro-
phoresis on 15% native polyacrylamide gels in TBE buffer
and visualized by autoradiography.
Cell viability assay
Cell viability was measured using Resazurin Fluorimetric
Cell Viability Assay Kit (Biotium, Inc.) according to the
manufacturer’s instructions. Brieﬂy, HeLa cells were
seeded at the conﬂuency of 20% in 10-cm plates. After
24h, cells were transfected with appropriate siRNA as
described above. One day after transfection, siRNA-
treated cells were harvested and seeded in a 96-well plate
at a density of 10 000 cells/well in a volume of 100mlo f
DMEM containing fetal calf serum and penicillin/
streptomycin. Next day, cells were treated with different
concentrations of diospyrin (compound D1; obtained
from Dr Banasri Hazra of Jadavpur University,
Kolkata) ranging from 0 to 100mM. Experiments were
Nucleic Acids Research, 2010,Vol.38, No. 22 8133carried out in hexaplicates for each drug concentration.
After 24h, cells were washed gently once with pre-warmed
PBS, and then a mixture of resazurin and DMEM (100ml)
in a ratio 1:10 was added in to each well. After 4h of incu-
bation at 37 C, cell viability was monitored by measuring
ﬂuorescence with excitation wavelength at 540nm and
emission wavelength at 590nm in a SpectraMax reader
M5 (Molecular Devices). The ﬂuorescent signal generated
from the assay is directly proportional to the number of
living cells in the sample. The percentage of survival of
diospyrin-treated cells was calculated relative to mock
(DMSO)-treated cells and plotted using GraphPad Prism
as mean±SD
RESULTS
RECQ5 binds to the CTD of RNAPII through
a conserved motif
In a yeast two-hybrid screen for proteins that interact with
the non-conserved C-terminal region of human RECQ5
(amino acids 411–991 fused to the LexA DNA-binding
domain), we isolated a clone from a human peripheral
blood cell cDNA library that encoded the CTD of the
largest subunit of RNAPII, RPB1 (amino acids 1266–
1970). This domain consists of evolutionary conserved
repeats of the heptapetide sequence YSPTSPS that serve
as a binding platform for proteins involved in transcrip-
tion and mRNA processing (17–19). Thus, our ﬁnding
suggests that RECQ5 is a novel RNAPII CTD-binding
protein.
During transcription, the CTD undergoes dynamic
phosphorylation on serine residues, producing different
phosphorylation patterns that predominate in individual
stages of the transcription cycle and determine the recruit-
ment of a speciﬁc set of proteins (17–19). Using the
MotifScan software, we found that the extreme
C-terminal region of RECQ5 (amino acids 910–950)
contains a putative phospho-CTD (P-CTD)-binding
motif, called a Set2–Rpb1-interacting (SRI) domain
(Figure 1A). This motif was initially identiﬁed as a
Ser2,5P-CTD-binding module in the yeast methyl-
transferase Set2, which catalyses histone H3 lysine 36
methylation during transcription (20). NMR studies
on the SRI domains of the yeast Set2 and its human
homologue SETD2 have revealed a novel CTD-binding
fold consisting of a left-turned three-helix bundle
(21,22). RECQ5 appears to contain only helices 1 and 2
that form the CTD-binding surface.
To show that the putative SRI motif of RECQ5 is
important for RECQ5 binding to the CTD of RNAPII,
we deleted it (amino acids 908–954) from the bait plasmids
carrying the full-length RECQ5 and RECQ5 411–991,
Figure 1. RECQ5 binds to the CTD of RNAPII through a SRI motif. (A) RECQ5 contains a CTD-binding motif. Top panel: domain organization
of RECQ5. R51B, RAD51-binding domain; PIM, PCNA-interacting motif. Bottom panel: alignment of RECQ5 homologues with selected Set2
homologues carried out using ClustalX. The locations of the SRI and PIM motifs are indicated by black lines. (B) Interaction of RECQ5 and its
mutants with the RNAPII CTD in the yeast two-hybrid system. Clones carrying the bait (RECQ5) and prey (CTD) plasmids were tested for
b-galactosidase activity using the pellet X-gal assay. Blue color indicates positive interaction. (C) Plot of absorbance at 620nm measured after 35min
in individual wells of the ELISA plate shown in (B) relative to wells with empty bait vector. The values represent the mean of three experiments.
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two-hybrid interaction with the CTD prey plasmid
isolated in our yeast two-hybrid screen. We found that
neither of these mutants interacted with RNAPII CTD
(Figure 1B and C). In contrast, the full-length RECQ5
as well as RECQ5 411-991 showed positive yeast
two-hybrid interaction with CTD (Figure 1B and C). A
previous study demonstrated that human CTD was
phosphorylated when expressed in yeast (23). Thus, our
data suggest that RECQ5 binds to the P-CTD of RNAPII
by means of the SRI domain.
It has been shown that RECQ5 binds to RNAPII
through a region including amino acids 396–617 (9).
Using a series of internal deletion variants of RECQ5,
we mapped more precisely the boundaries of this
domain to amino acids 515 and 640, respectively
(Supplementary Figure S1). Hereafter, this domain is
referred to as the Internal RNAPII-interacting (IRI)
domain. A deletion of the proximal part of the IRI
domain of RECQ5 that spans amino acids 515–568
(IRI) completely abolished binding of RECQ5 to the
hypophosphorylated form of RNAPII (RNAPIIA)
(Supplementary Figure S1C, Lane 4). In contrast, yeast
two-hybrid analysis indicated that the RECQ5 IRI
mutant bound to the RNAPII CTD to a similar extent
as wild-type RECQ5 (Figure 1B and C). Likewise, an
N-terminally truncated variant of RECQ5 of amino
acids 541–991 was found to interact with the RNAPII
CTD in the yeast two-hybrid system, although it was de-
fective in interacting with RNAPIIA (Figure 1B and C,
and data not shown).
RECQ5 speciﬁcally binds to Ser2,5-phosphorylated
CTD heptapeptide repeats
As an initial test of P-CTD binding, puriﬁed recombinant
versions of RECQ5 were subjected to SDS–PAGE and far
western analysis using a
32P-labeled GSTyCTD fusion
protein phosphorylated on Ser2 and Ser5 by yeast
CTDK-I (binding probe is expected to carry  25 doubly
phosphorylated repeats). The full-length RECQ5 bound
very well to the P-CTD fusion protein (Figure 2A, Lane
1), whereas RECQ5 deleted for the SRI domain did
not bind appreciably (Figure 2A, Lane 3). Likewise, a
C-terminal fragment containing the SRI domain
(residues 675–991) bound to P-CTD-like full-length
RECQ5, but a similar fragment lacking the SRI domain
did not show any binding (Figure 2A, Lanes 4 and 5).
Notably, RECQ5 missing only the IRI domain bound
P-CTD almost as well as the wild-type protein (Figure
2A, Lane 2 versus 1). These data indicate that RECQ5
binding to the P-CTD requires the SRI domain.
To check whether the SRI domain of RECQ5 has the
same binding speciﬁcity as the SRI domain of Set2 (22),
synthetic biotinylated peptides with three consensus CTD
heptapeptide repeats were immobilized on avidin-coated
beads to create afﬁnity resins. Because the full-length
RECQ5 showed signiﬁcant background interaction
with the TetraLink resin, we used the C-terminal
fragment of RECQ5 with and without the SRI domain
for the peptide-binding experiments. Binding was
evaluated with four different phosphorylated peptides:
(i) a non-phosphorylated peptide (NP); (ii) a peptide
with phospho-serines at position 2 of each repeat (2P3);
(iii) a peptide with phospho-serines at position 5 of each
repeat (5P3); and (iv) a peptide with phospho-serines at
positions 2 and 5 of each repeat (2,5P3) (Figure 2B). The
RECQ5 675-991 protein bound well to the resin with the
2,5P3 peptide: the protein was depleted from the column
ﬂow-through fraction and was only eluted from the resin
by 1M NaCl (Figure 2C, top panel). In contrast, RECQ5
675–991 did not bind detectably to resins with the NP,
2P3 or 5P3 peptides (Figure 2C, top panel). Moreover,
Figure 2. Effect of CTD phosphorylation status on RECQ5–CTD interaction. (A) Binding of RECQ5 and its mutants to in vitro phosphorylated
CTD. Top panel: Coomassie stained gel. Bottom panel: far western blot probed with
32P-labeled GSTyCTD fusion protein hyperphosphorylated with
CTDK-I. (B) Depiction of synthetic three-repeat CTD peptides used for the binding assay. The serines in blue are phospho-serines. (C) Immobilized
peptide-binding assay of RECQ5 675-991 on the four synthetic peptides. Fractions were analyzed by SDS–PAGE with Coomassie blue staining. OP,
onput; FT, ﬂow-through; W1 and W2, washes.
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column, conﬁrming that the SRI domain of RECQ5 is
required for interaction with the phosphorylated CTD
(Figure 2C, bottom panel). These results substantiate
that the SRI domain of RECQ5, like the SRI domain of
Set2, binds directly and speciﬁcally to CTD repeats with
phospho-serines at positions 2 and 5.
The SRI, but not IRI, domain of RECQ5 mediates its
binding to the hyperphoshorylated form of RNAPII
Next we compared the binding capabilities of wild-type
and mutant forms of RECQ5 to RNAPII holoenzyme
from human cells. To do so, RECQ5 proteins were
produced in bacteria as fusions with a CBD, bound to
chitin beads and incubated with a total extract of
HEK293T cells. RNAPII binding was analyzed by
western blotting using two different mouse monoclonal
antibodies against the RNAPII CTD: (i) H5 that recog-
nizes CTD repeats containing phospho-Ser2 and hence
selectively detects the hyperphosphorylated form of
RNAPII (IIO); and (ii) 7C2 that recognizes CTD repeats
irrespective of their phosphorylation status and, therefore,
can detect both RNAPIIO and RNAPIIA. As expected,
wild-type RECQ5 was found to bind both forms of
RNAPII (Figure 3, Lane 3). RECQ5 IRI was impaired
in binding to RNAPIIA but exhibited binding to
RNAPIIO with an extent similar to that of wild-type
RECQ5 (Figure 3, Lane 4). On the contrary, RECQ5
SRI showed binding to RNAPIIA but was impaired in
interacting with RNAPIIO (Figure 3, Lane 5). These data
indicate that the binding of RECQ5 to the hyper-
phosphorylated form of RNAPII is mediated by the SRI
domain of RECQ5.
RECQ5 associates with RNAPII-transcribed genes
within the region of productive elongation
RNAPII binds to the promoter with a CTD in the
non-phosphorylated state. CTD phosphorylation on
Ser5 is one of the ﬁrst steps in transcription initiation
and leads to the movement of the transcription complex
to a promoter-proximal pausing site. The escape of
RNAPII from the pausing site and subsequent productive
elongation of the transcript is associated with Ser2 phos-
phorylation of the CTD repeats (19). To investigate the
interaction between RECQ5 and RNAPII during the tran-
scription cycle, we used ChIP to characterize the distribu-
tion of RECQ5 along constitutively expressed genes. We
chose two genes, the ACTG1 gene encoding g-actin
(3.1kb) and the DHFR gene encoding dihydrofolate re-
ductase (30kb) (Figure 4A and B, top panels), which were
used previously to dissect the distribution of RNAPII and
its phosphorylated isoforms along the transcriptional unit
(24). Exponentially growing HeLa cells were crosslinked
with formaldehyde. Isolated chromatin fraction was
sonicated to shear the genomic DNA into small fragments
ranging from 200 to 500bp and subjected to immunopre-
cipitation using the following antibodies: (i) 8WG16 that
speciﬁcally recognizes non-phosphorylated CTD repeats;
(ii) ab5095 that speciﬁcally binds to phospho-Ser2 in
CTD; and (iii) anti-RECQ5 antibody raised against the
C-terminal fragment of RECQ5 spanning amino acids
675–991. After reversing the crosslinks, ChIP-enriched
DNA fragments were subjected to qPCR analysis using
primers amplifying the core promoter, different regions
within the transcriptional unit and an intergenic region
located downstream of each gene (Figure 4A and B, top
panels). Amplicon sizes ranged between 109 and 174bp.
In agreement with the published data (24), we found that
the non-phosphorylated RNAPII was bound exclusively
to the core promoter of the tested genes (Figure 4).
Ser2-phosphorylation of RNAPII was nearly absent at
the core promoter and accumulated in the body of each
gene (Figure 4). On both genes, the phospho-Ser2 signal
dramatically dropped in the 30-untranslated region
(30-UTR) and reached intergenic background levels
(Figure 4). Although RECQ5 could bind to the
hypophosphorylated form of RNAPII, it showed a rela-
tively low occupancy at the promoter region (Figure 4).
Notably, the RECQ5 distribution pattern was almost
identical to that of phospho-Ser2-CTD (Figure 4). Thus,
our data suggest that, during the RNAPII transcription
cycle, RECQ5 associates with the productive elongation
complex most likely through binding to Ser2,5P-CTD.
The SRI, but not IRI, domain of RECQ5 mediates its
association with RNAPII-transcribed genes
To investigate which of the two RNAPII-binding domains
of RECQ5 is responsible for the observed accumulation
of RECQ5 at the coding regions of the ACTG1 and
DHFR genes, the full-length RECQ5, RECQ5 IRI,
RECQ5 SRI and RECQ5 IRISRI, respectively,
were ectopically expressed in HEK293 cells as fusions
with GFP (Supplementary Figure S2) and subjected to
Figure 3. Binding of RECQ5 and its mutants to RNAPIIA and
RNAPIIO. Chitin beads coated with either wild-type (WT) or mutant
forms (IRI or SRI) of RECQ5 produced in bacteria as fusions
with the CBD were incubated with HEK293T cell extract. RNAPII
binding was analyzed by western blotting using the H5 antibody that
recognizes RNAPIIO (top panel) and 7C2 antibody that recognizes
both RNAPIIA and RNAPIIO (middle panel). RECQ5 proteins were
visualized by Ponceau S staining (bottom panel). Lane 1, 2% of input
material.
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ChIP experiments, cells were transfected with empty
vector expressing GFP only. The results obtained from
the qPCR analysis clearly indicated that the SRI domain
of RECQ5 was essential for the binding of RECQ5 to
the coding regions of the ACTG1 and DHFR genes
(Figure 5). In contrast, the IRI domain of RECQ5 was
found to be dispensable for its association with these genes
(Figure 5). To conﬁrm our ﬁnding, we also examined the
binding of RECQ5 and its mutants to the coding regions
of two other genes, namely CDKN1A (encoding p21) and
HSP70-2. As expected, GFP-tagged wild-type RECQ5
was largely enriched at the coding region of these two
genes (Figure 5). The mutants lacking the SRI domain,
RECQ5 SRI and RECQ5 IRISRI, failed to accumu-
late at these regions, while the RECQ5 IRI mutant
showed similar fold of enrichment as wild-type RECQ5
(Figure 5).
Point mutagenesis studies on the SRI domain of human
SETD2 identiﬁed several residues as critical for P-CTD
binding (22). We generated mutations in equivalent
residues of RECQ5 (F938L, K939A and R943A). Out of
these, the R943A mutation completely abolished the inter-
action of RECQ5 411–991 with the CTD in the yeast
two-hybrid system (Supplementary Figure S3A).
Likewise, the R943A mutation abolished the association
of RECQ5 with the coding region of the ACTG1 gene
(Supplementary Figure S3B).
Taken together, our results indicate that out of the two
RNAPII-interacting domains of RECQ5, the SRI domain
is necessary and sufﬁcient to mediate the association of
RECQ5 with the coding regions of RNAPII-transcribed
Figure 4. Distribution of RECQ5 and RNAPII along the ACTG1 and DHFR genes. (A) and (B) Top panels: schematic depiction of the ACTG1
and DHFR genes showing the locations of the transcription start site (+1), exons (grey boxes) and introns (lines connecting the grey boxes), the start
codon (ATG), the stop codon (TAA) and the polyadenylation signal (AATAAA). The location of the amplicons used in qPCR analysis is also
shown. The positions of the central base pair of each amplicon relative to the transcription start site are given in Supplementary Table S2. (A) and
(B) Bottom panels: plots of data from qPCR analysis. ChIPs of HeLa cells were performed with the 8WG16 antibody that speciﬁcally recognizes the
non-phosphorylated CTD (non-P-CTD) of RNAPII, the ab5095 antibody that speciﬁcally recognizes the Ser2 phosphorylated CTD (Ser2P-CTD) of
RNAPII and anti-RECQ5 antibody. Fold enrichment was calculated as a ratio of the amount of DNA estimated for a speciﬁc antibody versus the
amount of DNA estimated for the control IgG. The ampliﬁcation of an intergenic region served as an internal background control.
Nucleic Acids Research, 2010,Vol.38, No. 22 8137genes. Moreover, these data imply that the recruitment of
RECQ5 to the sites of transcription is dependent on Ser2,5
phosphorylation of the RNAPII CTD.
RECQ5 negatively affects cell viability upon inhibition
of spliceosome assembly
To understand the functional role of RECQ5 during
RNAPII transcription, we explored the possibility that
RECQ5 is involved in the cellular response to
co-transcriptionally formed R-loops. To this end, we
ﬁrst examined whether RECQ5 could unwind an RNA:
DNA hybrid duplex prepared by annealing of a synthetic
18-mer RNA oligonucleotide to M13mp2 ssDNA. We
found that RECQ5 failed to unwind this structure
although it could unwind the corresponding DNA:
DNA duplex (Supplementary Figure S4). This ﬁnding
suggests that RECQ5 does not disrupt R-loops in vivo.
Next, we evaluated the effect of RECQ5 depletion on
cell survival upon inhibition of spliceosome assembly,
which leads to the formation of R-loops. To do so,
RECQ5 was down-regulated in HeLa cells by RNA
interference using two different siRNAs (Figure 6A).
RECQ5-proﬁcient and RECQ5-deﬁcient cells were
treated with diospyrin that blocks spliceosome assembly.
It was shown that this Top1 kinase inhibitor caused the
same phenotypic defects as ASF/SF2 depletion (3).
Surprisingly, we found that RECQ5-proﬁcient cells dis-
played a much higher sensitivity to diospyrin than
RECQ5-deﬁcient cells (Figure 6B). These data suggest
that RECQ5 negatively affects cell viability in conditions
leading to the formation of R-loops.
DISCUSSION
Genetic ablation of RECQ5 helicase in mice results in
genomic instability and cancer susceptibility (6). Studies
in mouse and human cells have suggested that RECQ5
regulates HR by promoting disassembly of the RAD51
presynaptic ﬁlament (6). However, RECQ5 was also
found to interact with RNAPII in human cells, suggesting
a role in transcription (7–9). In this work, we provide
evidence that RECQ5 associates with RNAPII during
the productive elongation phase of transcription through
direct binding to the Ser2,5P-CTD of RPB1 by means of a
SRI motif located at the C-terminus of RECQ5. Although
RECQ5 could also bind to hypophosphorylated form of
RNAPII through an additional domain, herein referred as
IRI domain, it showed relatively low occupancy at the
promoter regions of RNAPII-transcribed genes, excluding
a role for RECQ5 during transcription initiation. In
addition, we show that RECQ5 negatively affects cell
viability upon inhibition of spliceosome assembly, which
can induce the formation of mutagenic R-loop structures.
Moreover, we demonstrate that RECQ5 cannot unwind
RNA : DNA duplexes in vitro, which excludes the possi-
bility the RECQ5 directly disrupts R-loops. Together,
these ﬁndings suggest that RECQ5 might play a role in
the maintenance of genomic stability during RNAPII
transcription.
Recently, Islam et al. (25) have also reported that the
SRI domain of RECQ5 mediates its binding to the
hyperphosphorylated form of RNAPII in human cells.
In addition, these authors have found that the IRI
domain of RECQ5 shares extensive homology with the
so-called KIX domain identiﬁed as a protein interaction
module in several RNAPII transcription regulators.
In agreement with our results, they demonstrated that
Figure 6. RECQ5 depletion alleviates sensitivity of human cells to
diospyrin. (A) Western blot analysis of extracts of HeLa cells trans-
fected with RECQ5 siRNA (siRECQ5 #1 and 2) and control siRNA
(siCtrl), respectively. Cells were harvested 72h post-transfection.
Blots were probed with antibodies against RECQ5 and b-tubulin
(loading control). (B) Graph showing the percentage survival of
RECQ5-proﬁcient and RECQ5-deﬁcient cells after treatment with dif-
ferent concentrations of diospyrin. Cell viability assays were performed
as described in ‘Materials and Methods’ section. Each data point rep-
resents mean ± SD (n=6). IB, immunoblotting.
Figure 5. The SRI domain of RECQ5 mediates its association with
RNAPII-transcribed genes. HEK293 cells were transfected either
with empty vector (mock) or with vectors expressing wild-type (WT)
or mutant (IRI, SRI or IRISRI) forms of RECQ5 as fu-
sions with GFP. Forty-eight hours post-transfection, chromatin was
immunoprecipitated by anti-GFP antibody and subjected to qPCR
analysis using primer pairs complementary to the coding regions of
the ACTG1, DHFR, CDKN1A and HSP70-2 genes (Supplementary
Table S2). Fold enrichment was calculated as a ratio of the qPCR
values obtained with RECQ5-transfected cells versus mock-transfected
cells.
8138 Nucleic Acids Research, 2010,Vol.38, No. 22mutations at conserved residues in the IRI/KIX domain
of RECQ5 abolished the interaction of RECQ5 with
RNAPIIA, but not with RNAPIIO (25). However, in
contrast to our observations, Islam et al. (25) found that
the IRI/KIX domain of RECQ5 could bind to both
RNAPIIA and RNAPIIO. This discrepancy may arise
from the use of different experimental approaches.
Whereas we analyzed binding of RNAPII from a cell
extract to beads coated with recombinant RECQ5
protein produced in bacteria, Islam et al. (25) monitored
RECQ5–RNAPII complex formation in vivo by
immunoprecipitation. Thus, it is possible that efﬁcient
binding of the IRI/KIX domain of RECQ5 to
RNAPIIO is dependent on a post-translational modiﬁca-
tion of RECQ5, which is absent if the protein is produced
in bacteria. Nevertheless, our ChIP experiments clearly
show that the IRI/KIX domain of RECQ5 does not
play a role in the association of RECQ5 with the coding
regions of RNAPII-transcribed genes, where the RNAPII
CTD exists in the hyperphosphorylated state. Further
studies are needed to elucidate the complex mode of the
RECQ5–RNAPII interaction. In particular, the site of
interaction for the IRI/KIX domain of RECQ5 on
RNAPII needs to be determined.
What is the exact role of RECQ5 during the elongation
phase of RNAPII transcription? Our experiments with
diospyrin suggest that RECQ5 might be involved in the
suppression of the DNA-damaging effects of RNAPII
transcription rather than in the repair of transcription-
induced DNA damage. Interestingly, a recent study by
Aygun et al. (10) showed that RECQ5 could directly
inhibit RNAPII transcription in vitro in a manner depend-
ent on its IRI/KIX domain, which led the authors to
propose a model in which RECQ5 promotes genome sta-
bility by regulating RNAPII transcription itself. In line
with this hypothesis, Islam et al. (25) demonstrated that
the IRI/KIX, but not the SRI, domain of RECQ5 was
required for suppression of sister chromatid exchange
and resistance to camptothecin-induced DNA damage.
However, it should be noted that the in vitro transcription
system used by Aygun et al. (10) lacked CTD kinase
activity responsible for CTD phosphorylation on Ser2
during transcription. Our experiments with the RECQ5
SRI mutant have indicated that hyperphosphorylation
of RNAPII prevents binding of RECQ5 to RNAPII via
the IRI/KIX domain, suggesting that Ser2 CTD phos-
phorylation may alleviate the inhibitory effect of
RECQ5 on RNAPII transcription so that RECQ5 could
not affect RNAPII transcription during productive elong-
ation in vivo. However, it is possible that a formation of an
R-loop during transcription could trigger a domain inter-
action switch in the RECQ5–RNAPII complex to adopt
the inhibitory arrangement, which would prevent further
extension of the R-loop structure and hence diminish its
DNA-damaging effect. Our ﬁnding of negative effect of
RECQ5 on cell viability under conditions that favor
R-loop formation is consistent with this hypothesis.
Future work will clarify the molecular mechanism of this
phenomenon to shed light on the biological processes that
enforce genomic stability during transcription.
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